FD
FDMDF.US 4DMedical Limited
- Market cap
- USD 967M
- P/E
- -
- P/B
- 8.27x
- ROE
- -120.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is FDMDF.US undervalued?
Graham numberThe Graham number of 4DMedical Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
4DMedical Limited fundamental analysis
No fundamental analysis for 4DMedical Limited yet.
4DMedical Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 4DMedical Limited
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; L…
Full company profile4DMedical Limited financial statements
4DMedical Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.93K | 789K | 695K | 1.23M | 217K | 1.05M | 719K | 3.05M | 5.85M | 7.05M |
| Gross Profit | -2.93M | -3.01M | -3.73M | -8.13M | 125K | 281K | -24.3M | 2.81M | 5.39M | -38.0M |
| Operating Income | -4.68M | -5.17M | -7.02M | -16.0M | -13.7M | -22.2M | -30.7M | -46.6M | -29.2M | -57.4M |
| EBITDA | -4.55M | -5.01M | -6.74M | -14.2M | -18.0M | -35.3M | -42.1M | -31.9M | -42.2M | -51.9M |
| Net Income | -3.97M | -3.94M | -6.49M | -22.0M | -21.4M | -24.6M | -31.5M | -36.0M | -30.1M | -204M |
| EPS | -0.03 | -0.03 | -0.04 | -0.08 | -0.08 | -0.08 | -0.10 | -0.10 | -0.07 | -0.03 |
| Balance Sheet | ||||||||||
| Total Assets | 4.95M | 5.45M | 9.02M | 15.8M | 92.6M | 74.3M | 92.9M | 120M | 94.8M | 365M |
| Total Liabilities | 1.70M | 1.67M | 4.47M | 27.6M | 9.28M | 14.8M | 21.5M | 49.1M | 30.6M | 195M |
| Shareholders' Equity | 3.25M | 3.78M | 4.56M | -11.8M | 83.4M | 59.5M | 71.5M | 70.9M | 64.2M | 170M |
| Cash & Short-term Investments | 1.15M | 1.66M | 3.09M | 8.43M | 80.9M | 51.1M | 69.6M | 30.6M | 6.88M | 278M |
| Total Debt | - | 1.00M | 3.00M | 16.5M | 1.69M | 6.24M | 5.14M | 5.12M | 4.31M | 3.21M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.16M | -3.38M | -5.78M | -7.65M | -14.5M | -25.3M | -22.7M | -30.9M | -34.5M | -31.2M |
| Capital Expenditure | 1.13M | 1.43M | 1.28M | 1.16M | 353K | 3.08M | 1.61M | 303K | 85.8K | 948K |
| Free Cash Flow | -3.29M | -4.81M | -7.06M | -8.81M | -14.9M | -28.3M | -24.3M | -31.2M | -34.6M | -32.2M |
| Ratios | ||||||||||
| ROE | -122.3% | -104.2% | -142.5% | - | -25.7% | -41.3% | -44.0% | -50.7% | -46.8% | -120.1% |
| ROA | -80.3% | -72.2% | -71.9% | -138.9% | -23.1% | -33.1% | -33.9% | -30.0% | -31.7% | -56.0% |
| Net Profit Margin | -206,438.3% | -498.8% | -934.0% | -1,783.0% | -9,872.2% | -2,332.6% | -4,378.0% | -1,179.8% | -513.7% | -2,895.1% |
| Debt to Equity | - | 0.26x | 0.66x | - | 0.02x | 0.10x | 0.07x | 0.07x | 0.07x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
4DMedical Limited dividends
4DMedical Limited has not paid dividends in the last 10 fiscal years.
Who owns 4DMedical Limited
- Insiders 16.57%
- Institutions 25.41%
- Public & others 58.02%
- Shares outstanding 602M
- Free float 498M
4DMedical Limited company profile
- Company name
- 4DMedical Limited
- Ticker
- FDMDF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 181
- Fiscal year end
- June
- Address
- Melbourne Connect, Carlton, VIC, Australia, 3053
- Phone
- 61 3 9545 5940
- Website
- 4dmedical.com
About 4DMedical Limited
4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. 4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.
4DMedical Limited management
10- Mr. Julian Sutton B.Sc., C.F.A.Executive Chairman
- Dr. Andreas Fouras B.E., M.A.I.C.D., Ph.D.Founder, MD, CEO & Director
- Mr. Matt TuckerChief Commercial Officer
- Mr. Chris CoxChief Financial Officer
- Ms. Beth Plunkett J.D.General Counsel
- Dr. Aidan Jamison B.E., Ph.D.Senior Vice President of Engineering
- Ms. Rachael TenkatenSenior Vice President of Product
- Dr. Greg T. Mogel M.D.Chief Medical Officer
- Mr. David Hannes B.S., M.B.A.Senior Vice President of Global Business Development
- Mr. Hamish George B.Com., C.A.Company Secretary